Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
 
 
  
  The rules say that Proton Beam Therapy (PBT) is a technology for delivering conformal external beam 
radiation with positively charged atomic particles to a well-defined treatment volume. PBT is approved by the 
U.S. Food and Drug Administration. Due to its unique dose deposition characteristics, PBT can, in certain 
situations, deliver the prescribed target dose while giving a lower dose to normal tissues as compared to 
photon-based forms of external beam radiotherapy. 
 
Photon beams deposit their greatest amount of energy beneath the patient's surface with a gradual reduction in 
energy deposition along the beam path as photons pass through the target and then through an exit point out of 
the body. In contrast, the physical profile of a beam of proton particles allows for the majority of its energy to 
be deposited over a very narrow range of tissue at a depth largely determined by the energy of the proton beam. 
A proton beam deposits relatively less radiation energy upon entering the body compared to a photon beam. 
The energy deposition of the proton beam then rapidly increases over a narrow range of tissue at a desired 
depth to produce an intense dose distribution pattern called the Bragg peak. Beyond the Bragg peak, energy and 
dose deposition rapidly decrease, resulting in the absence of any significant exit dose deposited in normal tissue 
beyond the target. 
 
PBT Treatment Planning 
PBT can allow for radiation treatment plans that are highly conformal to the target volume. PBT planning 
defines the necessary field sizes, gantry angles and beam energies needed to achieve the desired radiation dose 
distribution. 
 
An assessment of patient suitability for PBT is an important step in the process of care. Changes in the density 
and composition of tissues in the path of the beam have much greater impact on the delivered dose for protons 
than photons. Tissue interfaces, especially those with large differences in electron density, can lead to larger or 
unacceptable dosimetric uncertainties in PBT for certain patients. PBT treatment planning is a multi-step 
process and shares functions common to other forms of external beam radiotherapy planning: 
 
PBT Treatment Delivery 
    Proton delivery methods can be described in one of two forms: scattering or scanning. 
 
        In scattered deliveries, the beam is broadened by scattering devices, beam energies are combined by 
mechanical absorbers and the beam is shaped by placing material such as collimators and compensators into 
the proton path. 
        In scanning deliveries, the beam is swept laterally over the target with magnets instead of with scattering 
devices. Collimators and range compensators are still sometimes used for lateral and distal beam shaping, but 
field specific hardware is not always required because the scanning magnets allow the lateral extent of the 
beam to be varied with each energy level, a technique sometimes called intensity-modulated proton therapy 
(IMPT). 
 
    The basic requirement for all forms of PBT treatment delivery is that the technology must accurately 
produce the calculated dose distribution described by the PBT plan. PBT dose distributions are sensitive to 
changes in target depth and shape and thus, changes in patient anatomy during treatment may require repeat 
planning. Such a change must be documented. 
 
    Precise delivery is vital for proper treatment. Therefore, imaging techniques such as stereoscopic X-ray or 
CT scan (collectively referred to as Image Guided Radiation Therapy or IGRT) should be utilized to verify 
accurate and consistent patient and target setup for every treatment fraction. 
 
    PBT is considered reasonable in instances where sparing the surrounding normal tissue cannot be adequately 
achieved with photon-based radiotherapy and is of added clinical benefit to the patient. Examples of such an 
advantage might be: 
         A photon-based technique would increase the probability of clinically meaningful normal tissue toxicity 
by exceeding an integral dose-based metric associated with toxicity. 
        The same or an immediately adjacent area has been previously irradiated, and the dose distribution within 
the patient must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue. 
     
Prostate Cancer 
    Coverage and payments of proton beam therapy for prostate cancer will require: 
        Physician documentation of patient selection criteria (stage and other factors as represented in the NCCN 
guidelines); 
        Documentation and verification that the patient was informed of the range of therapy choices, including 
risks and benefits.  
 
You can find these rules in the Local Coverage Determination (LCD) Proton Beam Therapy L35075. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.